MABp1 as a novel antibody treatment for advanced colorectal cancer: a randomised, double-blind, placebo-controlled, phase 3 study

The Lancet Oncology

Volumn 18, Issue 2, 2017, Pages 192-201

  Hickish, Tamas ^a,b,c   Andre, Thierry ^d   Wyrwicz, Lucjan ^e   Saunders, Mark ^f   Sarosiek, Tomasz ^g   Kocsis, Judit ^h   Nemecek, Radim ⁱ   Rogowski, Wojciech ^j   Lesniewski Kmak, Krzysztof ^k   Petruzelka, Lubos ^l   Apte, Ron N ^m   Mohanty, Prasant ⁿ   Stecher, Michael ⁿ   Simard, John ⁿ   de Gramont, Aimery ^o  

^a POOLE HOSPITAL NHS FOUNDATION TRUST   (United Kingdom)

^b ROYAL BOURNEMOUTH HOSPITAL   (United Kingdom)

^c BOURNEMOUTH UNIVERSITY   (United Kingdom)

^d HÔPITAL SAINT ANTOINE   (France)

^e INSTITUTE OF ONCOLOGY   (Poland)

^f CHRISTIE HOSPITAL   (United Kingdom)

^g Departments of Gastroenterological Oncology   (Poland)

^h UNIVERSITY OF DEBRECEN   (Hungary)

ⁱ MASARYK MEMORIAL CANCER INSTITUTE   (Czech Republic)

^j Olsztyn Cancer Center   (Poland)

^k Gdynia Cancer Centre Hospital Gdynia   (Poland)

^l CHARLES UNIVERSITY   (Czech Republic)

^m BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

ⁿ XBiotech USA Inc   (United States)

^o Institut Hospitalier Franco Britannique   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALKALINE PHOSPHATASE; ANTINEOPLASTIC AGENT; ASPARTATE AMINOTRANSFERASE; C REACTIVE PROTEIN; IRINOTECAN; MABP1 ANTIBODY; OXALIPLATIN; PLACEBO; UNCLASSIFIED DRUG; MABP1 MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY;

ABDOMINAL PAIN; ABNORMAL SUBSTRATE CONCENTRATION IN BLOOD; ADULT; ADVANCED CANCER; AGED; ALKALINE PHOSPHATASE BLOOD LEVEL; ANEMIA; ANOREXIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; ASTHENIA; CANCER PROGNOSIS; CANCER SURVIVAL; COLORECTAL CANCER; CONSTIPATION; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG WITHDRAWAL; FATIGUE; FEMALE; HUMAN; INFLAMMATION; LEAN BODY WEIGHT; MAJOR CLINICAL STUDY; MALE; MORBIDITY; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPHIL LYMPHOCYTE RATIO; PHASE 3 CLINICAL TRIAL; PLATELET LYMPHOCYTE RATIO; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; TREATMENT DURATION; WEIGHT REDUCTION; ADENOCARCINOMA; CANCER STAGING; CLINICAL TRIAL; COLORECTAL TUMOR; FOLLOW UP; IMMUNOLOGY; LYMPH NODE METASTASIS; MIDDLE AGED; PATHOLOGY; PROGNOSIS; SECONDARY; SURVIVAL RATE; VERY ELDERLY;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; COLORECTAL NEOPLASMS; DOUBLE-BLIND METHOD; FEMALE; FOLLOW-UP STUDIES; HUMANS; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; SURVIVAL RATE;

EID: 85009354487     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(17)30006-2     Document Type: Article

References (30)

1. 1 Lozano, R, Naghavi, M, Foreman, K, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 380 (2012), 2095–2128.
2. 2 Obrand, DI, Gordon, PH, Incidence and patterns of recurrence following curative resection for colorectal carcinoma. Dis Colon Rectum 40 (1997), 15–24.
3. 3 European Medicines Agency Oncology Working Party. Guideline on the evaluation of anticancer medicinal products in man. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2013/01/WC500137128.pdf, Dec 13, 2012 (accessed Dec 2, 2016).
4. 4 Dinarello, CA, Interleukin-1α neutralisation in patients with cancer. Lancet Oncol 15 (2014), 552–553.
5. 5 Tjomsland, V, Spångeus, A, Välilä, J, et al. Interleukin 1α sustains the expression of inflammatory factors in human pancreatic cancer microenvironment by targeting cancer-associated fibroblasts. Neoplasia 13 (2011), 664–675.
6. 6 Tomimatsu, S, Ichikura, T, Mochizuki, H, Significant correlation between expression of interleukin-1α and liver metastasis in gastric carcinoma. Cancer 91 (2001), 1272–1276.
7. 7 Ricote, M, García-Tuñón, I, Bethencourt, FR, Fraile, B, Paniagua, R, Royela, M, Interleukin-1 (IL-1α and IL-1β) and its receptors (IL-R1, IL-RII and IL-1Ra) in prostate carcinoma. Cancer 100 (2004), 1388–1396.
8. 8 Miller, LJ, Kurtzman, SH, Anderson, K, et al. Interleukin-1 family expression in human breast cancer: interleukin-1 receptor antagonist. Cancer Invest 18 (2000), 293–302.
9. 9 Voronov, E, Shouval, DA, Krelin, Y, et al. IL-1 is required for tumor invasiveness and angiogenesis. Proc Natl Acad Sci USA 100 (2003), 2645–2650.
10. 10 Salven, P, Hattori, K, Rafii, S, Interleukin-1α promotes angiogenesis in vivo via VEGFR-2 pathway by inducing inflammatory cell VEGF synthesis and secretion. FASEB J 16 (2002), 1471–1473.
11. 11 Apte, RN, Dotan, S, Elkabets, M, et al. The involvement of IL-1 in tumorigenesis, tumor invasiveness, metastasis and tumor-host interactions. Cancer Metastasis Rev 25 (2006), 387–408.
12. 12 Hong, DS, Janku, F, Naing, A, et al. Xilonix, a novel true human antibody targeting the inflammatory cytokine interleukin-1 α, in non-small cell lung cancer. Invest New Drugs 33 (2015), 621–631.
13. 13 Hong, DS, Hui, D, Bruera, E, et al. MABp1, a first-in-class true human antibody targeting interleukin-1α in refractory cancers: an open-label, phase 1 dose-escalation and expansion study. Lancet Oncol 15 (2014), 656–666.
14. 14 Yeh, KY, Li, YY, Hsieh, LL, et al. Analysis of the effect of serum interleukin-6 (IL-6) and soluble IL-6 receptor levels on survival of patients with colorectal cancer. Jpn J Clin Oncol 40 (2010), 580–587.
15. 15 Stone, RL, Nick, AM, McNeish, IA, et al. Paraneoplastic thrombocytosis in ovarian cancer. N Engl J Med 366 (2012), 610–618.
16. 16 Quinten, C, Coens, C, Mauer, M, et al. Baseline quality of life as a prognostic indicator of survival: a meta-analysis of individual patient data from EORTC clinical trials. Lancet Oncol 10 (2009), 865–871.
17. 17 Wallengren, O, Lundholm, K, Bosaeus, I, Diagnostic criteria of cancer cachexia: relation to quality of life, exercise capacity, and survival in unselected palliative care patients. Support Care Cancer 21 (2013), 1569–1577.
18. 18 Jonker, DJ, O'Callaghan, CJ, Karapetis, CS, et al. Cetuximab for the treatment of colorectal cancer. N Engl J Med 357 (2007), 2040–2048.
19. 19 IAEA. Dual energy x ray absorptiometry for bone mineral density and body composition assessment: IAEA human health series no. 15, 2011, International Atomic Energy Agency, Vienna.
20. 20 Toombs, RJ, Ducher, G, Shepherd, JA, De Souza, M, The impact of recent technological advances on the trueness and precision of DXA to assess body composition. Obesity 20 (2012), 30–39.
21. 21 Tukey, JW, Exploratory data analysis, 1977, Addison-Wesley, Boston, MA, 43–44.
22. 22 Rajiput, S, Wilber, A, Roles of inflammation in cancer initiation, progression and metastasis. Front Biosci (School Ed) 2 (2010), 176–183.
23. 23 Terzić, J, Grivennikov, S, Karin, E, Karin, M, Inflammation and colon cancer. Gastroenterology 138 (2010), 2101–2114.
24. 24 Gao, F, Liang, B, Reddy, ST, Farias-Eisner, R, Su, X, Role of inflammation-associated microenvironment in tumorigenesis and metastasis. Curr Cancer Drug Targets 14 (2014), 30–45.
25. 25 Ran, S, The role of TLR4 in chemotherapy-driven metastasis. Cancer Res 75 (2015), 2405–2410.
26. 26 Jäger, D, Taverna, C, Zippelius, A, Knuth, A, Identification of tumor antigens as potential target antigens for immunotherapy by serological expression cloning. Cancer Immunol Immunother 53 (2004), 144–147.
27. 27 Turano, A, Caruso, A, The role of human autoantibodies against gamma-interferon. J Antimicrob Chemother 32:suppl A (1993), 99–105.
28. 28 Shapir, T, Shoenfeld, Y, Facing the enigma of immunomodulatory effects of intravenous immunoglobulin. Clin Rev Allergy Immunol 29 (2005), 185–199.
29. 29 Singel, KL, Segal, BH, Neutrophils in the tumor microenvironment: trying to heal the wound that cannot heal. Immunol Rev 273 (2016), 329–343.
30. 30 Daenen, LG, Roodhart, JM, van Amersfoort, M, et al. Chemotherapy enhances metastasis formation via VEGFR-1-expressing endothelial cells. Cancer Res 71 (2011), 6976–6985.